<DOC>
	<DOCNO>NCT03055403</DOCNO>
	<brief_summary>This Phase I first-in-human design evaluate safety , tolerability pharmacokinetics single ascend dos M201-A administer single continuous intravenous injection Healthy Japanese subject .</brief_summary>
	<brief_title>First-in-Human Dose Escalation Study M201-A Healthy Japanese Subjects</brief_title>
	<detailed_description>Not Provided</detailed_description>
	<criteria>Subjects must satisfy follow criterion enrol study : Japanese Healthy Male subject Age 20 less 40 year age Body Mass Index ( BMI ) 18.5 less 25.0 kg/m2 Written inform consent must obtain voluntary basis assessment perform . The presence follow exclude subject enrollment : Presence past medical history hepatic impairment , renal impairment , cardiovascular disease , gastrointestinal disease others inappropriate participate clinical trial Past medical history cancer , cerebral infarction cardiac infarction Presence past medical history allergic reaction idiosyncrasy food , medicinal substance metallic material QTcF &gt; 450ms screen examination NTproBNP &gt; 125 pg/mL screen examination Any risk factor Torsades de Pointes include heart failure , hypokalemia , long QT interval syndrome due family medical history</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>